Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence?
Positive-pressure ventilation implies a sealed room, usually with an anteroom to facilitate the donning of protective clothing, airflows of at least 12 air changes per hour and high-efficiency particulate air (HEPA) to prevent infection in susceptible patients. Laminar airflow (LAF) involves much greater air changes, expense and inconvenience to the patient due to noise and draughts. There are few, if any, truly controlled trials on the impact of positive-pressure ventilation and the prevention of invasive aspergillosis (IA); most are observational studies conducted during an outbreak or retrospective analyses of the incidence of IA over periods of time when a variety of preventative interventions were introduced. Therefore, it is often difficult to determine the specific impact of positive-pressure ventilation with HEPA in leading to a reduction in IA. During periods of hospital demolition or construction, HEPA significantly reduces the aspergillus spore counts and in many studies, the incidence of IA, but other measures such as enhanced cleaning, the sealing of windows and the use of prophylactic anti-fungal agents are also important. On balance, the additional expense and inconvenience of LAF does not appear to be justified. Where positive-pressure ventilation is installed, it is imperative that the system be monitored to ensure that the pressure differentials and air changes are appropriate. Whilst there is a role for positive-pressure ventilation in reducing the incidence of IA, we need a better definition of the importance of hospital-acquired IA compared with community-acquired infection and of the relationship between strains of Aspergillus species isolated from the environment and those strains causing infection.
Humphreys
H
H
Department of Clinical Microbiology, RCSI Education and Research Centre, Beaumont Hospital, Dublin, Ireland. hhumphreys@rcsi.ie
D000391:Air Microbiology; D001228:Aspergillosis / Q000517:prevention & control* / Q000635:transmission; D001232:Aspergillus fumigatus / Q000302:isolation & purification; D003428:Cross Infection / Q000382:microbiology / Q000517:prevention & control* / Q000635:transmission; D004780:Environment, Controlled; D017408:Guidelines as Topic; D016867:Immunocompromised Host; D007494:Ireland; D008021:Life Support Systems; D010357:Patient Isolators; D011312:Pressure; D014691:Ventilation / Q000379:methods*